![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The proceeds will be used to accelerate the next generation of precision medicines for immune-mediated diseases and fibrotic diseases by leveraging its proprietary Mirador360TM development engine to rapidly advance multiple programs.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 21, 2024